Vacines Market Report: Global Insights, Opportunities, and Forecast 2024 -2032

The global vaccines market was valued at USD 90.28 billion in 2023 and is expected to grow from USD 87.57 billion in 2024 to USD 159.28 billion by 2032, registering a compound annual growth rate (CAGR) of 7.8% during the forecast period. In North America, the vaccines market is projected to increase from USD 37.57 billion in 2023 to USD 38.75 billion in 2024.

The global vaccines market has witnessed substantial growth in recent years, driven by increasing awareness of immunization, rising government initiatives, and advancements in biotechnology. Vaccines play a crucial role in preventing infectious diseases and improving public health outcomes across all age groups. The market encompasses a broad range of products, including pediatric, adult, travel, and therapeutic vaccines. The growing prevalence of infectious diseases, coupled with the emergence of new pathogens and pandemic threats, continues to drive demand. Moreover, technological innovations in vaccine development-such as mRNA platforms, recombinant technologies, and adjuvants-are transforming the landscape. Strategic collaborations between pharmaceutical companies, research institutions, and global health organizations are further fueling market expansion. Despite challenges such as vaccine hesitancy and supply chain constraints, the vaccines market is poised for continued growth, supported by sustained investments in R&D and expanding immunization programs worldwide.

List Of Key Companies Profiled:

• GlaxoSmithKline plc. (U.K.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Emergent BioSolutions, Inc. (U.S.)
• CSL Limited (Australia)
• Inovio Pharmaceuticals, Inc. (U.S.)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)

Get a Free Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/vaccines-market-101769

Market Segmentation:

By Type Analysis
The recombinant/conjugate/subunit segment led the market in 2023 due to high efficacy, safety, and ease of large-scale production. It is expected to maintain dominance with the highest CAGR, supported by product launches like GSK's Arexvy and ongoing recombinant vaccine R&D.

By Route of Administration Analysis
Parenteral vaccines held the largest market share in 2023 and will continue leading through 2032. However, the oral vaccines segment is projected to grow faster due to ease of use, safety, and cost-efficiency, with firms like iosBio driving innovation.

By Disease Indication Analysis
Viral diseases accounted for the largest share in 2023, supported by a strong vaccine development pipeline and new product approvals. Bacterial diseases are expected to grow at a higher CAGR due to increased sales of pneumococcal, meningitis, and DTP vaccines.

By Age Group Analysis
The pediatric segment held the largest value share in 2023, driven by national immunization programs and high global DTP3 coverage. The adult segment is projected to grow faster, supported by over 80% of pipeline vaccines targeting adult populations.

By Distribution Channel Analysis
Government suppliers led the market in 2023 and are expected to maintain dominance due to high-volume procurement and global outreach. Organizations like UNICEF and GAVI play a vital role in delivering millions of doses, especially in low- and middle-income regions.

Report Coverage:
The global vaccines market research report delivers a comprehensive analysis, emphasizing major companies, various product types, and their applications. It also provides valuable insights into current market trends and highlights significant industry advancements. Furthermore, the report examines multiple factors that have driven the market's growth in recent years.

Drivers and Restraints:
R&D Investments and Regulatory Progress to Stimulate Market Growth
The emphasis on creating innovative vaccines, supported by a strong pipeline from both emerging and major pharmaceutical companies, is fueling global market expansion. Moreover, growing investments in research and development, along with efforts to gain regulatory approvals, are enhancing vaccines market growth. Leading companies such as GSK, Sanofi, Merck, and Pfizer are set to drive industry growth with their extensive product pipelines. However, the high cost per dose, such as USD 100 for dengue and USD 121 for Hepatitis vaccines as per CDC's updated vaccine price list for 2023, poses a significant challenge, especially for low-income regions.

Explore the full research report with detailed insights and TOC:

https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769

Regional Insights:
North America led the global vaccines market in 2023 and is expected to maintain its dominance due to strong vaccination awareness, robust manufacturers, and supportive government health policies. The U.S. market is projected to reach USD 62.37 billion by 2032, driven by a strong R&D pipeline. Asia Pacific is poised for significant growth, with Japan currently leading, while China and India grow rapidly thanks to large populations and high vaccine coverage. Europe is forecasted to see steady growth, supported by high vaccination rates and mandatory immunization policies, with Hib vaccine coverage at 94%. Meanwhile, Latin America, the Middle East, and Africa are emerging markets fueled by rising immunization demand and government programs, with Brazil leading the region thanks to its longstanding National Immunization Program.

Key Industry Developments:
In February 2024, UNICEF strengthened its partnership with Azerbaijan's Ministry of Health to improve child vaccination efforts.

Fortune Business InsightsTM Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
US +1 833 909 2966 (Toll Free)
UK +44 808 502 0280 (Toll Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

Fortune Business InsightsTM offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.